How much weight can you lose on tirzepatide or semaglutide?
In US label trials of about 16 months, adults without diabetes lost 15% to 21% of their weight on average on tirzepatide (Mounjaro, Zepbound) and about 15% on semaglutide 2.4 mg (Wegovy). Loss was fastest in the first months, then slowed. People with type 2 diabetes lost less, and much of the weight returned after stopping.
How much weight did people lose in the trials?
In the US label trials, adults without diabetes lost 15.0% to 20.9% on tirzepatide and 14.9% on semaglutide 2.4 mg, on average.1,2
The main US Zepbound trial ran for 72 weeks. Average loss was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on a placebo (dummy injection).1 The main US Wegovy trial ran for 68 weeks, with 14.9% lost, against 2.4% on placebo.2 Everyone in these trials was also advised to eat about 500 fewer calories a day and to be more active.1,2
The averages hide a wide spread. On tirzepatide 15 mg, 56.7% lost at least 20% of their weight, but 9.1% lost under 5%.1 On semaglutide 2.4 mg, 30.2% lost at least 20% and 16.5% lost under 5%.2 For a 100 kg person, a 15% loss is 15 kg.
The US Wegovy label also reports other forms. The 7.2 mg injection gave 18.8% over 72 weeks, against 3.9% on placebo. The 25 mg tablet gave 13.6% over 64 weeks, against 2.4%.2
Type 2 diabetes lowers the numbers. With diabetes, average loss was 12.8% to 14.7% on Zepbound and 9.6% on Wegovy 2.4 mg.1,2
How fast does the weight come off?
Loss is fastest in the first months and then slows, and the US health agency NIH says most weight loss happens within the first 6 months.3
Both medicines start on a low dose. The US Zepbound label starts at 2.5 mg for 4 weeks, a dose “not approved as a maintenance dosage,” then allows 2.5 mg steps after at least 4 weeks on each.1 The Wegovy injection reaches its 2.4 mg maintenance dose at week 17.2
Two US label trials show the pace in people who stayed on treatment. In one Wegovy trial, average weight fell from 107.2 kg to 96.1 kg in the first 20 weeks, about 10%. Those who carried on lost another 7.9% over the next 48 weeks.2 In a Zepbound trial, people lost 20.9% in the first 36 weeks. Those who stayed on it lost another 5.5% over the next 52 weeks.1
Those figures leave out people who stopped early. In the Zepbound trial, 14.4% stopped before week 36, most often because of side effects.1
Faster loss has costs. The US Wegovy label says substantial or rapid weight loss can raise the risk of gallstones.2 The US Zepbound label links hair loss to weight reduction, reported by 7.1% of women on Zepbound against 1.3% of women on placebo. Between 4.8% and 6.7% stopped Zepbound because of side effects, against 3.4% on placebo.1 On Wegovy injection, 6.8% stopped for side effects, against 3.2%.2 Our side effects guide covers the risks.
Does the weight stay off after stopping?
Much of it came back. In trials where people stopped the medicine, they regained a large share of the lost weight within about a year.1,4
In the STEP 1 extension, 327 people who had lost 17.3% on semaglutide 2.4 mg stopped treatment at week 68. By week 120 they had regained 11.6 percentage points, which the authors call two-thirds of their prior weight loss. All of its analyses were exploratory.4
In the Zepbound trial above, people switched to placebo at week 36 regained 14.0% of their weight over the next 52 weeks.1 In the Wegovy trial, people switched to placebo at week 20 regained 6.9% by week 68.2
What do people on GLP-1 medicines report about how much and how fast they lose?
From public patient forums: 1,694 Reddit threads in r/Zepbound, r/Mounjaro, r/WegovyWeightLoss, r/mounjarouk, r/Semaglutide and r/Ozempic, read from October 2025 to October 2026. Personal reports, not medical evidence.
What people describe
- Matches NIH Many describe a big drop in the first weeks, then a slower, steadier pace. NIH says most weight loss takes place within the first 6 months.3
- Matches the label Several lost little on the starting doses and say loss began at higher ones. The US Zepbound label calls 2.5 mg a starting dose, not a maintenance dose.1
- Matches the label Several stress that results vary widely and that trial averages are not a promise. In the US Zepbound trial, 56.7% on 15 mg lost at least 20%, while 9.1% lost under 5%.1
- Matches the label Several report problems they tie to fast loss, among them hair shedding and gallstones. The US labels link hair loss to weight reduction and say rapid loss can raise gallstone risk.1,2
- Matches the trial A few describe weight returning after stopping or a gap in treatment, though a handful kept it off. In the STEP 1 extension, people regained two-thirds of their loss within a year of stopping.4
Advice people share
- Matches the label Several suggest staying on the lowest dose that works and stepping up with the prescriber when loss stalls or hunger returns. Both US labels say to weigh response and tolerability when choosing a maintenance dose.1,2
- Matches the label Several advise tracking food honestly for a while, because the medicine makes eating less easier but does not replace it. Both US labels pair the medicine with a reduced-calorie diet and more activity.1,2
- Label says otherwise Several describe stretching the gap between injections, taking in-between doses or stepping up faster than scheduled. The US Wegovy label sets one injection a week on the same day, and the US Zepbound label raises the dose in 2.5 mg steps after at least 4 weeks.2,1
In your country
The trials are the same everywhere, and Canada’s Zepbound monograph gives the US figures, but the EU, UK and Australian tirzepatide labels report the main trial with higher averages, and the UK adds a 5% check.5,6,7,8
Australia
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.
Label: The Australian Mounjaro Product Information reports the main 72-week trial as 16.0% to 22.5% average loss, against 2.4% on placebo. It counts results differently from the US label, which includes everyone randomly assigned.7,1
Emergency number: 000
Canada
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.
Label: The answer above applies.
Emergency number: 911
France
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).
Label: The EU Mounjaro product information reports the main 72-week trial as 16.0% to 22.5% average loss, against 2.4% on placebo. It counts results differently from the US label, which includes everyone randomly assigned.5,1
Emergency number: 15 or 112
Germany
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.
Label: The EU Mounjaro product information reports the main 72-week trial as 16.0% to 22.5% average loss, against 2.4% on placebo. It counts results differently from the US label, which includes everyone randomly assigned.5,1
Emergency number: 112
India
Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).
Label: We could not open an Indian label for this page, so this answer relies on the US labels and EU product information.1,2,5,9
Emergency number: 112
Saudi Arabia
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.
Label: We could not open a Saudi label for this page, so this answer relies on the US labels and EU product information.1,2,5,9
Emergency number: 997 or 911
United Arab Emirates
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.
Label: We could not open a UAE label for this page, so this answer relies on the US labels and EU product information.1,2,5,9
Emergency number: 998 for an ambulance, or 999
United Kingdom
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.
Label: The UK Mounjaro SmPC reports the main 72-week trial as 16.0% to 22.5% average loss, against 2.4% on placebo, counted differently from the US label.6 The UK SmPCs also add a 5% check for weight management. On Mounjaro, it comes 6 months after reaching the highest tolerated dose. On Wegovy, it comes after 6 months of treatment. Anyone who has not lost at least 5% of their starting weight by then needs a decision on continuing.6,10
Emergency number: 999
United States
Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).
Label: The answer above applies.
Emergency number: 911
Contact your prescriber or a doctor right away if you have severe stomach pain that will not go away, with or without vomiting, sometimes felt in your back. The US Zepbound label lists it as a sign of pancreatitis (an inflamed pancreas).1
Read the full picture
Related questions
Sources
- US Zepbound (tirzepatide) prescribing information and Medication Guide, Eli Lilly (sections 2.1, 2.2, 5.4, 6.1 including Table 1 and Hair Loss, 14 Tables 2 and 6). uspl.lilly.com
- US Wegovy (semaglutide) prescribing information, Novo Nordisk, on DailyMed (sections 2.1, 2.2 Table 1, 5.3, 14 Tables 8, 9, 11 and 12, 17). dailymed.nlm.nih.gov
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, part of NIH). Prescription medications to treat overweight and obesity. niddk.nih.gov
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553–64. PMID 35441470. pubmed.ncbi.nlm.nih.gov
- EU Mounjaro (tirzepatide) product information (SmPC section 5.1, SURMOUNT-1 Table 8), European Medicines Agency. ema.europa.eu
- UK Mounjaro KwikPen (tirzepatide) SmPC, sections 4.2 and 5.1, electronic Medicines Compendium. medicines.org.uk
- Australian Mounjaro (tirzepatide) Product Information, section 5.1. medsinfo.com.au
- Canadian Zepbound (tirzepatide injection) Product Monograph, Health Canada Drug Product Database. pdf.hres.ca
- EU Wegovy (semaglutide) product information (SmPC section 5.1), European Medicines Agency. ema.europa.eu
- UK Wegovy 2.4 mg FlexTouch (semaglutide) SmPC, section 4.2, electronic Medicines Compendium. medicines.org.uk
- American College of Emergency Physicians. Know When to Go to the ER. emergencyphysicians.org
Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 16, 2026. The shares who lost under 5%, the 20-week percentage and the 15 kg example are our arithmetic from the label tables. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write